Blueprint Medicines Corporation

As major pharmaceutical companies continue investing heavily in immunology –with Sanofi’s recent $9.1bn acquisition of Blueprint Medicines underscoring the sector’s strategic importance – San Franci

Sanofi is cementing its position as an immunology powerhouse by agreeing to acquire Blueprint Medicines Corp of the US and its soon-to-be blockbuster Ayvakit in a deal that could be worth up to $9.5bn

Sanofi’s immunology pipeline has suffered a couple of high-profile setbacks recently so the proposed acquisition of Blueprint Medicines Corp and Ayvakit, its already-approved therapy for advanced sy

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed